Proton pump inhibitors (PPIs) may be linked to concentration and memory problems in individuals with a history of breast cancer.
New research suggests that proton pump inhibitors (PPIs) may negatively affect cognition in individuals with a history of breast cancer.1
The findings, which were published in the Journal of Cancer Survivorship, found that the commonly-used acid reflux drug may potentially contribute to memory and concentration problems in this population.1
However, in order for a causal effect to be established, the authors noted that further investigation should include a clinical trial controlling PPI doses and obtaining cognitive data.
Previous research has suggested that off-label use of PPIs in patients with cancer may increase tumors’ responsiveness to chemotherapy while protecting the digestive system, but long-term studies on the effects of PPI use in this population are limited.2
The study authors conducted a secondary analysis using data from 3 previous clinical trials examining fatigue, a yoga intervention, and vaccine response in 551 patients with breast cancer and those with a history of the disease. Individuals in the studies reported their use of prescribed and OTC medications and rated their cognitive function throughout the study period. A total of 88 participants reported taking PPIs. Data from both PPI users and non-users were included and the studies controlled for a variety of factors that could affect cognition, including depression or other illnesses, type of cancer treatment, age, and education.1
Across all 3 studies, PPI users reported more cognitive problems overall than non-users. In the first study, PPI users reported more severe concentration problems (p=0.039), but not memory problems (p=0.17) than non-users. PPI users in the second study had more severe concentration problems (p=0.022) compared with non-users, but not memory problems or symptoms on the BCPT (ps=0.11). In study 3, PPI users reported more severe memory problems (p=0.002), poorer overall cognitive function (p=0.006), lower quality of life related to cognitive problems (p=0.005), greater perceived cognitive impairment (p=0.012), and poorer cognitive abilities (p-0.046), but not more severe concentration problems (p=0.16), compared with non-users, according to the study.1
Overall, the findings indicated that cognitive problems reported by PPI users were between 20% and 29% more severe than issues reported by non-users. Additionally, the analysis showed that at least two-thirds of breast cancer survivors using PPIs had been taking them for between 6 months and 2 years.1
“I thought there could be a cognitive effect from taking PPIs, particularly in this population, because breast cancer survivors are already at risk for cognitive decline,” lead author Annelise Madison, a graduate student in clinical psychology at Ohio State University, said in a press release about the results.2 “PPIs are over the counter and generally considered safe so there haven’t been many long-term trials, especially looking at cognitive outcomes, because nobody was really thinking that would be a downstream effect.”
According to Madison, the findings raise more questions regarding the cognitive recovery of PPI users after chemotherapy and warrant further investigation.2
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.